Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: porphyrin-based cancer therapeutics - OncoSelect Therapeutics

Drug Profile

Research programme: porphyrin-based cancer therapeutics - OncoSelect Therapeutics

Latest Information Update: 19 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OncoSelect Therapeutics
  • Developer OncoSelect Therapeutics; University of Texas Health Science Center at San Antonio
  • Class Porphyrins
  • Mechanism of Action Image enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 15 May 2023 Early research development is ongoing in USA
  • 15 May 2023 OncoSelect Therapeutics has patent protection for patent related to "Porphyrin Compounds and Compositions to Treat Cancer" in Hong Kong, China and Mexico
  • 15 May 2023 OncoSelect Therapeutics has patents pending for patent related to "Porphyrin Compounds and Compositions to Treat Cancer" in Canada, the European Union, India and Japan
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top